 NEW YORK, Aug. 11, 2021 PRNewswire -- Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. Reata or the Company NASDAQ: RETA. Such investors are advised to contact Robert S. 